New DES: A new step forward?

Minerva Cardioangiologica

Volumn 60, Issue 1, 2012, Pages 41-56

  Ko, B S ^a   Meredith, I T ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Drug eluting stents; Polymers; Thrombosis

Indexed keywords

CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; POLYMER; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

ATHEROSCLEROSIS; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADATION; CORONARY STENT; DEVICE SAFETY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

ABSORBABLE IMPLANTS; DRUG-ELUTING STENTS; FORECASTING; HUMANS; POLYMERS; PROSTHESIS DESIGN;

EID: 84858857803     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119:3198-206.
2. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010;121:2645-53.
3. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72.
4. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42. (Pubitemid 352001347)
5. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10. (Pubitemid 46986103)
6. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.
7. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-7.
8. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
9. Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW et al. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. Eurointervention 2011;7:74-83.
10. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003;92:463-6. (Pubitemid 36959888)
11. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21. (Pubitemid 32550070)
12. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8. (Pubitemid 36438988)
13. Birgelen C. Twente, A Prospective, Randomised Trial of Zotarolimus-Eluting Stents and Everolimus-Eluting Stents in Patients with Coronary Artery Disease. Presented at the Transcatheter Cardiovascular Therapeutics Meeting, San Francisco, November 2011 2011.
14. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-77.
15. Stone GW, Rutledge D, Krishnankutty S, Hermiller J, Serruys P, Mao VW et al. Stent Thrombosis and Dual Antiplatelet Interruption, Insights from the Xience V Everolimus Eluting Coronary Stent System Trials. Presented at the Transcatheter Cardiovascular Therapeutics Meeting, San Francisco, November 2011.
16. Raber L, Magro M, Stefanini GG, Kalesan B, Van Domburg R, Onuma Y et al. Bern-Rotterdam Cohort Study -Newer genreation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents. Presented at the Congress of the European Society of Cardiology, Paris, August 2011.
17. Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation 2011;124:1283-7.
18. Mack MJ, Banning AP, Serruys PW, Morice MC, Taeymans Y, Van Nooten G et al. Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome. Ann Thorac Surg 2011 [Epub ahead of print].
19. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.
20. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011;32:2125-34.
21. Raber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011;123:2819-28.
22. Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Amman EM et al 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41.
23. King SB, 3rd, Smith SC, Jr., Hirshfeld JW, Jr., Jacobs AK, Morrison DA, Williams DO et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172-209.
24. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
25. Brar SS, Ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-54.
26. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 2002;40:403-9. (Pubitemid 34833152)
27. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9.
28. Menown IB, Noad R, Garcia EJ, Meredith I. The platinum chromium element stent platform: from alloy, to design, to clinical practice. Adv Ther 2010;27:129-41.
29. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011;57:1700-8.
30. Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW et al. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. Eurointervention 2011;7:84-90.
31. Kereiakes DJ. Novel Drug Eluting Coronary Stents Nearing Approval in the United States. Cardiac Interventions Today 2011;5:29-34.
32. Meredith I, Stone GW, Teirstein PS. Platinum Small Vessel: 12-Month Outcomes. Presented at EUROPCR, Paris, France May 20 2011.
33. Hanratty CG, Walsh SJ. Longitudinal compression: a "new" complication with modern coronary stent platforms - time to think beyond deliverability? EuroIntervention 2011;7:872-7.
34. Williams PD, Mamas MA, Morgan KP, El-Omar M, Clarke B, Bainbridge A et al. Longitudinal stent deformation: a retrospective analysis of frequency and mechanisms. Eurointervention 2011 [Epub ahead pf print].
35. Pitney M, Pitney K, Jepson N, Friedman D, Nguyen-Dang T, Matthews J et al. Major stent deformation/pseudofracture of 7 Crown Endeavor/Micro Driver stent platform: incidence and causative factors. EuroIntervention 2011;7:256-62.
36. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009;120:141-9.
37. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8. (Pubitemid 40982311)
38. Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J et al. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multi-center comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv 2010;3:556-64.
39. Ormiston JA, Webber B, Webster MW. Stent longitudinal integrity bench insights into a clinical problem. JACC Cardiovasc Interv. 2011 Dec;4(12):1310-7. Epub 2011 Nov 30.
40. Gao R. Firehawk Abluminal Groove Filled Bioabsorbable Polymer Sirolimus Stents: Updat on the First in Man, TARGET I and TARGET II Studies. Paper presented at: Transcatheter Cardiovascular Therapeutics, November 8, 2011; San Francisco, CA 2011.
41. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009;30:2441-9.
42. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.
43. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011 [Epub ahead of print].
44. Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010;31:165-76.
45. Yazdani SK, Vorpahl M, Nakano M, Su SH, Kolodgie FD, Virmani R. In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent. Eurointervention 2011;7:835-43.
46. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N et al. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv 2008;1:193-200.
47. Wykrzykowska J, Serruys P, Buszman P, Linke A, Ischinger T, Klauss V et al. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). Eurointervention 2011;7:789-95.
48. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005;25:748-53. (Pubitemid 40463864)
49. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008;29:1975-82.
50. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010;56(10 Suppl):S43-78.
51. Grube E. BioFreedom First In Man progress report. Presented at Transcatheter Cardiovascular Therapeutics; September 24, 2009, San Francisco, CA 2009.
52. Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009;95:1489-94.
53. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31.
54. Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S et al 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 2010;55:2536-43.
55. Carrie D. NEXT A Prospective, Randomized Trial Comparing Cre8, a Polymer-Free Stent Eluting Sirolimus, to a Paclitaxel-Eluting Stent. Paper presented at: Transcatheter Cardiovascular Therapeutics, November 11, 2011; San Francisco, CA 2011.
56. Wentzel JJ, Whelan DM, van der Giessen WJ, van Beusekom HM, Andhyiswara I, Serruys PW et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000;33:1287-95.
57. Tortoriello A, Pedrizzetti G. Flow-tissue interaction with compliance mismatch in a model stented artery. J Biomech 2004;37:1-11. (Pubitemid 37532624)
58. Gijsen FJ, Oortman RM, Wentzel JJ, Schuurbiers JC, Tanabe K, Degertekin M et al. Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries. Am J Cardiol 2003;92:1325-8. (Pubitemid 37431144)
59. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907. (Pubitemid 351384734)
60. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
61. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with denovo coronary artery disease: the ABSORB trial. Eurointervention 2011 [Epub ahead of print].
62. Serruys P. 5-Year Cohort A and 2-Year Cohort B Results: Integrated Insights. Presented at Transcatheter Cardiovascular Therapeutics; November 8, 2011, San Francisco, CA 2011.
63. Okamura T, Garg S, Gutierrez-Chico JL, Shin ES, Onuma Y, Garcia-Garcia HM et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. Eurointervention 2010;5:932-8.
64. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122:2301-12.
65. Ormiston J. Lessons Learned from FIM Bioresorbable Scaffolds: "The GOOD, The BAD and The UGLY". Presented at Therapeutics Cardiovascular Tehcniques, 2011, San Francisco, November 8, 2011 2011.
66. Prabhu S, Schikorr T, Mahmoud T, Jacobs J, Potgieter A, Simonton C. Engineering assessment of the longitudinal compression behaviour of contemporary coronary stents. Eurointervention 2011 [Epub ahead of print].
67. Meredith I, Verheye S, Dubois C, Dens J, Fajadet J, Carrie D et al. Clinical and Angiographic outcomes of the EVOLVE Trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. Presented at Therapeutics Cardiovascular Tehcniques, 2011, San Francisco, November 11, 2011.
68. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial - Phase 2. Circ Cardiovasc Interv 2009;2:188-95.
69. Ormiston J. Micell Crystalline sirolimus elution from an absorbable polymer - DESSOLVE 1 preliminary trial results. Presented at Therapeutics Cardiovascular Tehcniques, 2011, San Francisco, November 11, 2011 2011.
70. Abizaid A. Excella BD Randomized Trial 6 Month Results. Presented at Therapeutics Cardiovascular Tehcniques, 2011, San Francisco, November 11, 2011 2011.
71. Simon D. NEVO Program: Final Perspectives. Presented at Therapeutics Cardiovascular Tehcniques, 2011, San Francisco, November 11, 2011 2011.
72. Haude M. The REMEDEE Study: A Randomized Comparison of a Combination Sirolimus Eluting EPC Capture Stent with a Paclitaxel Eluting Stent. Presented at Therapeutics Cardiovascular Tehcniques, 2011, San Francisco, November 11, 2011 2011.
73. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006 Jan 17;113:273-9.